Biocon has gained a certificate of good manufacturing practice (GMP) from the European Medicines Agency’s Irish inspection authority for its Malaysian manufacturing site where it produces its insulin glargine biosimilar, Semglee, referencing Lantus.
Biocon has gained a certificate of good manufacturing practice (GMP) from the European Medicines Agency’s Irish inspection authority for its Malaysian manufacturing site where it produces its insulin glargine biosimilar, Semglee, referencing Lantus.
The site was inspected in May 2019, according to Biocon. The company indicated in a statement that the approval will allow the company to expand its capacities with new large-scale devices as it seeks to meet the growing demand for insulins in Europe, where the biosimilar has been authorized for sale since March 2018.
Since its authorization by the European Commission, the biosimilar, developed in partnership with Mylan, has become available in key markets that include the United Kingdom. The biosimilar is also approved in other major regulatory territories, including Australia.
Semglee is not yet approved in the United States, however, where the product received a Complete Response Letter (CRL) from the FDA in 2018 after having been evaluated under the 505(b)(2) regulatory pathway for follow-on drugs (as insulins and some other biological products will not be regulated as biologics in the United States until March 2020).
At the time of the CRL, a Mylan representative told The Center for Biosimilars® that the partnership had agreed with the FDA to provide additional clinical data in support of a manufacturing site change from Bangalore to Malaysia and that the companies had incorporated the CRL into their plan.
Prior to the CRL, the company received a Form 483 from the FDA, inclusive of 6 observations, after an inspection of the Malaysia facility. Another inspection of the site in June and July 2019 yielded another Form 483 with 12 observations. Biocon indicated that it will respond with a corrective and preventive action plan.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.